Autolus Therapeutics
AUTL
89 hedge funds and large institutions have $277M invested in Autolus Therapeutics in 2025 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 25 increasing their positions, 28 reducing their positions, and 19 closing their positions.
2,815% more call options, than puts
Call options by funds: $583K | Put options by funds: $20K
18% more capital invested
Capital invested by funds: $236M → $277M (+$41.5M)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
2.03% less ownership
Funds ownership: 54.39% → 52.36% (-2%)
7% less funds holding
Funds holding: 96 → 89 (-7)
11% less repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 28
26% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MCO
MAK Capital One
New York
|
+$6.13M |
| 2 |
BNP Paribas Asset Management
Paris,
France
|
+$5.16M |
| 3 |
AC
Armistice Capital
New York
|
+$2.92M |
| 4 |
Schroder Investment Management Group
London,
United Kingdom
|
+$1.62M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$717K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$7.51M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$4.19M |
| 3 |
AAA
Affinity Asset Advisors
New York
|
-$2.85M |
| 4 |
Renaissance Technologies
New York
|
-$2.73M |
| 5 |
PL
Perpetual Ltd
Sydney, New South Wales,
Australia
|
-$784K |
AUTL Hedge Fund Activity: Q4 2025 in Review
89 of the 8,266 institutional investors tracked by Wall St. Rank reported a position in Autolus Therapeutics (AUTL) for Q4 2025, worth a combined $277M — up 18% from $236M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of AUTL and 14 opened new positions — a net loss of 5 holders — while 28 trimmed existing stakes and 25 added.
The largest buyer was MAK Capital One, adding an estimated $6.13M. The largest seller was Citadel Advisors, cutting an estimated $7.51M.
- 89 institutional investors held Autolus Therapeutics (AUTL) as of Q4 2025, down from 96 in Q3 2025.
- Funds reported $277M of Autolus Therapeutics stock for Q4 2025, up 18% quarter-over-quarter.
- 14 funds opened new Autolus Therapeutics positions in Q4 2025 and 19 closed out, a net change of -5 holders.
- The largest Autolus Therapeutics buyer in Q4 2025 was MAK Capital One, an estimated $6.13M added.
- The largest Autolus Therapeutics seller in Q4 2025 was Citadel Advisors, an estimated $7.51M sold.
Based on aggregated 13F filings for Q4 2025.